Kornimate/medical-research-clean huggingface dataset:
detection of circulating tumor cells for the diagnostic of pancreatic adenocarcinoma.

Conditions: Circulating Tumor Cells; Pancreatic Adenocarcinoma; Circulating Tumor DNA (KRAS); CA 19.9

Summary: histological proof is a crucial and necessary step for appropriate care in oncology. in the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number (15-20 %) of localized tumor accessible to surgical resection. in most cases, invasive endoscopic explorations are necessary for histological diagnosis before deciding of the most appropriate treatment (palliative chemotherapy or radiochemotherapy). the endoscopic ultrasound with fine needle aspiration (eus-fna) is currently considered as the first-line endoscopic procedure for the cytological diagnosis of solid pancreatic tumors. the technique is performed under general anesthesia with sensitivity for the diagnosis of adenocarcinoma of 80% in case of a single procedure and 92% in situations where three different procedures are required. eus-fna has to be performed by a physician properly trained for this type of interventional endoscopy. some severe complications may occur but are relatively rare in expert centers (bleeding, perforation, complications of general anesthesia ...). diagnostic alternative approach is biological with research in the peripheral blood of markers of tumor disease. it is possible to detect indirect markers which are molecules produced by tumor tissue (eg ca19.9) and direct markers which reflect the presence of tumor biological material (circulating tumor cells (ctcs) or circulating tumor dna). the value of detection of ctcs is not determined for the diagnostic and therapeutic management of pancreatic cancer. indeed, no study has evaluated the diagnosis performance of circulating markers with eus-fna, the reference method for the diagnosis of unresectable forms.


Eligibility criteria:
inclusion criteria: * patient is male or female, and \> 18 years of age * patient has a nonmetastatic solid pancreatic tumor (proved by ct thoraco-abdomino-pelvic) without histological evidence * patient is referred for surgical treatment or biliopancreatic endoscopic ultrasound with fine needle aspiration (eus-fna) of a pancreatic mass * patient has agree to participate by giving written informed consent exclusion criteria: * metastatic pancreatic tumor * cancer or other hematologic malignancy during treatment or in remission for less than 5 years. * minor patient under 18 years * contraindication to surgical treatment or contraindication to the biliopancreatic eus-fna * patient under guardianship * pregnant or lactating women

Keywords: circulating tumor cells pancreatic adenocarcinoma circulating tumor dna (kras) ca 19.9
medical versus surgical treatments of rectal endometriosis

Conditions: Endometriosis

Summary: the purpose of this study is to determine whether, in women with deep endometriosis involving the rectum and not intending to get pregnant, continuous hormonal treatment would be followed by better digestive functional outcomes than curative rectal surgery. are included women from 35 to 50 years presenting with deep endometriosis infiltrating at least the muscular layer of the rectum and not having pregnancy intention. the main outcome concerns the quality of digestive function 24 after the onset of the treatment, assessed using a composite variable: patient considering that digestive function is normal and the knowles-eccersley-scott-symptom questionnaire (kess score) \ 100. secondary outcomes are: presence of severe constipation, increased frequency of daily bowel movements, anal incontinence, postoperative dysuria, biberoglou \& behrman score, quality of life sf36 score, kess score, giqli, wexner score of anal continence, bristol stools score, the rate of postoperative complications, medical treatment adverse outcomes, the rate of additional endoscopic and surgical procedures. the randomization is central, once the physician asses the diagnosis, explain the study's principle and rece in the arm a, the patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months. in the arm b, patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months. the number of subjects required is 78 (39 on each arm). inclusions period is estimated at 24 months. the length of the follow up is 24 months. the patients have 8 visits in the arm a, and 7 visits in the arm b. eleven french tertiary referral centres will enrol patients in the trial.


Eligibility criteria:
inclusion criteria: * age 35-50 * no menopause * digestive complaints: defecation pain, dyskesia, diarrhea, constipation, rectorrhage * imaging assessment revealing deep endometriosis involving at least the muscular rectal layer * no intention to get pregnant during the following 24 months * negative urinary pregnancy test * affiliated to the french social security system exclusion criteria: * pregnant women or during the breastfeeding * pregnancy intention or lack of efficient contraception * unexpected rectal endometriosis intraoperatively revealed * refus of one of treatments planned in the two arms * severe disease requiring surgical treatment in emergency (bowel occlusion, ureteral stenosis or hydronephrosis), severe dyspareunia * contraindications to hormonal treatment or surgery * major thromboembolic factors * antecedents of inflammatory bowel diseases, cancer or colorectal resection * vaginal hemorrhage with undetermined etiology

Keywords: deep endometriosis; rectal endometriosis; rectal shaving; colorectal resection; bowel endometriosis
determination of adipocyte parameters in iliac crest biopsies from post menopausal women

Conditions: Osteoporosis; Postmenopausal

Summary: to evaluate the effect of estrogen treatment on adipocytic and osteoblastic parameters by histomorphometrically measuring adipocyte volume (av/tv) and adipocyte numbers in goldner's stained iliac crest bone biopsy specimens collected from subjects recruited in the study (irb number 21b85). the adipocytic parameters will be then correlated with osteoblastic parameters obtained previously during the course of the initai study involving the effect of transdermal estrogen on bone turnover in postmenopausal osteoporotic women.


Eligibility criteria:
post-menopausal osteoporotic women
the influence of age and gender on tongue pressure and swallowing tongue pressure

Conditions: Swallowing Disorder

Summary: the main topic of the research is to investigate the tongue's strength when swallowing. there has been much foreign literature on tongue strength. iowa oral performance instrument also has norms for reference, but the data are all taken from non-asian people such as caucasians. in this case, the credibility of the norms are decreased in domestic, and we also lack norm data of tongue strength when swallowing. through the research, we can establish normative data belonging to the domestics, provide usable data for domestic researchers and clinical staff, and explore whether there are differences in age and gender in data between taiwanese and foreigners.

swallowing refers to the process by which food enters the stomach from the mouth. it is the physiological mechanism by which humans take in water and nutrients. it is a vital activity for individual survival. the physiological mechanism of swallowing has four major stages, oral preparation, oral cavity, pharynx, and esophagus. each stage has its physiological mechanism, which depends on the different nerve and muscle structures. in the oral stage, our tongue plays an important role. whether in the formation or transition of the food bolus, it must rely on the tongue to perform its normal functions. the main topic of the research is to explore the strength of the tongue when swallowing. the purpose is to discuss the influence of gender and age on swallowing tongue pressure. we expect to recruit 80 subjects and divide them into three groups according to their age: 20 to 39 years old, 40 to 59 years old, and 60 to 79 years old, with 13 to 14 males and females in each group, using iowa oral performance instrument measures the subject's maximum tongue pressure, average swallowing tongue pressure, and the ratio of the maximum tongue pressure used when swallowing, to explore whether age and gender affect tongue strength when swallowing.

Eligibility criteria:
inclusion criteria: * aged twenty and above. exclusion criteria: * based on self-representation, has the disease of the nervous system, included stroke, brain trauma, parkinson's disease, dementia, etc. * based on self-representation, has head and neck cancers. * based on self-representation, had any history of swallowing disorders. * based on self-representation, has obvious cognition impairment or language disorder that will affect measure procedure.

Keywords: swallowing function age gender
study of intravenously (iv) infused etentamig in combination with an oral cereblon e3 ligase modulatory drug (celmod) agent assessing adverse events and change in disease activity in adult participants with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: multiple myeloma (mm) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. the purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon e3 ligase modulatory drug (celmod) agent in adult participants with relapsed/refractory (r/r) multiple myeloma (mm). adverse events and change in disease state will be assessed. etentamig is an investigational drug being developed for the treatment of r/r mm. study doctors put the participants in groups called treatment arms. multiple doses of etentamig in combination with iberdomide will be explored. each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. approximately 135 adult participants with r/r mm will be enrolled in the study in approximately 50 sites worldwide. in phase 1 participants will receive escalating intravenous (iv) etentamig in combination with oral iberdomide. in phase 2 participants will receive iv etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at an approved institution (hospital or clinic). the effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.

b-cell maturation antigen (bcma) chimeric antigen receptor t-cell (car-t) or bcma antibody-drug conjugate (adc) are allowed.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance of 0 to 1. * must have confirmed diagnosis of relapsed/refractory multiple myeloma (rrmm) after the participant's last treatment, as outlined in the protocol. * all participants must have measurable diseases per central laboratory as outlined in protocol exclusion criteria: * has received prior etentamig treatment. * prior exposure to bcma-targeted therapy as noted in the protocol. * has received prior cereblon e3 ligase modulatory drug (celmod) (iberdomide or mezigdomide).

Keywords: multiple myeloma cereblon e3 ligase modulatory drug celmod iberdomide etentamig abbv-383
half-dose depot triptorelin versus reduced-dose daily buserelin

Conditions: Infertility

Summary: the purpose of this study is to determine whether half-dose depot triptorelin are as effective as reduced-dose daily buserelin in the controlled ovarian stimulation for intracytoplasmic sperm injection and embryo transfer

significant doubts remain about which type of gnrh agonists \[gnrha\] administration to be used in controlled ovarian stimulation \[cos\] cycles. the use of a single-dose depot long-acting gnrha instead of a daily low dose preparation would be more comfortable for patients, however, inducing a profound pituitary desensitization, it increases the number of gonadotropin ampoules and the duration of the cos cycle without improving pregnancy rates or other clinical outcomes. thus, some authors recommend a reduction of both dose and/or duration of gnrha administration. halving the dose of depot triptorelin, for instance, has been studied against its full dose administration since 1992 with rather similar clinical outcomes. half-dose depot leuprolide acetate has also resulted in comparable clinical outcomes with standard daily injections in long gnrha protocol. reducing the daily doses of short acting gnrha has been advocated to demonstrate equivalent results to standard doses. to our knowledge, however, the reduced daily doses have not been evaluated against half dose depot forms in long gnrha protocols. thus, we originally compared a half-dose depot triptorelin with reduced daily doses of short-acting buserelin in a long protocol for intracytoplasmic sperm injection and embryo transfer \[icsi/et\] cycles.

Eligibility criteria:
inclusion criteria: * candidate for icsi/et * 35 years old or younger * serum fsh less than 10 iu/l on day three of the previous menstrual cycle * no more than two previous ivf/icsi attempts * no planned percutaneous epididymal sperm aspiration \[pesa\] * no planned testicular sperm extraction \[tese\] * no known history or risk of severe hyperstimulation * no evidence of hydrosalpinx * no major systemic disease * no uterine abnormality * no previous ovarian surgery

Keywords: half-dose depot triptorelin reduced-dose daily buserelin controlled ovarian stimulation long protocol icsi
5-year objective and subjective results of a mid-urethral sling

Conditions: Stress Urinary Incontinence

Summary: evaluate 5-year objective and subjective cure rates after implant of the retropubic align urethral support system.

between june 2007 and december 2008, the investigators performed 155 align mid-urethral slings in patients who were only receiving this operation. very few studies have outcomes at 5 years of greater. the aim of this prospective cohort study is to evaluate five-year objective and subjective cure rates. secondary endpoints will assess failure risk factors and describe any complications of the retropublic align urethral support system five years postoperatively.

Eligibility criteria:
inclusion criteria: * women * complaint of stress urinary incontinence * underwent align urethral support system from june 2007-december 2008 exclusion criteria: * concommitant procedures

Keywords: mid-urethral sling align urethral support system tension free vaginal tape cough stress test pelvic exam pfdi-20 pfiq ssq urinary retention mesh erosion urodynamics
relapse prevention for bipolar type-ii disorder

Conditions: Bipolar Disorder; Depression

Summary: this 62-week study will compare the safety and effectiveness of fluoxetine (prozac®), lithium, the combination of these two medications, and placebo in treating and preventing recurrent depressive episodes in people with bipolar type ii disorder.

bipolar ii (bp ii) disorder is characterized by a high recurrence of major depressive episodes (mde), and it is associated with substantial illness and deaths. unfortunately, relatively little attention has been given to treatment of bp ii. concern that patients may switch from depressed to manic states during treatment of mde has impeded the development of effective treatments for bp ii mde. bp ii mde patients are treated initially with fluoxetine for 10 weeks. patients who recover from mde are then randomized to receive a relapse-prevention treatment of fluoxetine, lithium, a combination of fluoxetine and lithium, or placebo for 1 year. patients undergo clinical and laboratory evaluations, including physical examinations, bloodwork, thyroid function tests, electrocardiogram (ecg), urinalysis, and ham-d, ymr, cgi-s, cgi-i, and adverse events scales. for information on a related study, please follow this link: http://clinicaltrials.gov/show/nct00602537

Eligibility criteria:
inclusion criteria: * bipolar ii depression
aesthetic and functional outcomes of eyelid reconstruction after excision of periocular tumors

Conditions: Eyelid Defects; Periocular Tumors

Summary: * to determine the aesthetic and functional outcomes of different techniques used in eyelid reconstruction following periocular defects. * to determine the complications of eyelid reconstruction and how to prevent them

patients will undergo the following : direct eyelid closure will be done in small defects with or without canthyolysis larger defects will be reconstructed with anterior and posterior lamella reconstruction using grafts and flaps patients will be followed up as regard * the stability of flap or graft * the vertical and horizontal measurements of palbepral fissure * detection of any complications * donor site follow up * patient degree of satisfaction

Eligibility criteria:
inclusion criteria: * patients with periocular tumors and candidate for excision exclusion criteria: * patients with history of radiotherapy or chemotherapy

Keywords: eyelid reconstruction periocular tumors
smartglass-guided ercp with cannulation of native papilla 1.0

Conditions: Biliary Tract Diseases; Pancreatic Diseases

Summary: the aim of this prospective randomized study is to evaluate whether telemedical assistance via smartglasses is equivalent to physical presence in teaching endoscopic retrograde cholangiopancreaticography (ercp) in terms of examination success and safety. endoscopic papilla cannulation is a key skill for successful ercp and therefore a measurable primary endpoint of the study. this can be measured as the time (in seconds/minutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct).

in sparsely populated regions of a country and where there is a lack of experienced specialists, it may not always be possible to have an experienced ercp examiner present during an examination. therefore, telemedical examination assistance via a connection to data glasses worn by the examiner is a possible option to replace the physical presence of an instructor or experienced ercp examiner. the aim of this prospective randomized study is to evaluate whether telemedical assistance via smart glasses is equivalent to physical presence in terms of examination success and safety. endoscopic papilla cannulation is a key skill for successful ercp and therefore a measurable primary endpoint of the study. this can be measured as the time (in seconds/minutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct). in addition to other efficacy endpoints, adverse events, which are expected to be rare, will be documented at 48-hour intervals and calculated as a rate. telemedical 'live' support of an ercp via data glasses has not yet been demonstrated or tested in a trial. to ensure the safety of the examination under these circumstances, the training examiner is present in the neighbouring room and can physically assist or take over the examination at any time if necessary.

Eligibility criteria:
inclusion criteria * adult patients aged ≥ 18 years without previous papillotomy exclusion criteria * cannulation of the minor papilla necessary * significant comorbidity * haemodynamic instability * pregnant women * refusal or inability to give written informed consent for the study * instructor had to perform the examination himself/herself

Keywords: telemedicine training technique cholangiopancreatography, endoscopic retrograde
effect of active breathing exercises in stroke patients with respiratory rhythm disorder

Conditions: Respiratory Rhythm Disorder

Summary: the goal of this clinical trial is to explore the effect of active breathing exercises in stroke patients with respiratory rhythm disorder. patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. on this basis, the observation group will be given active breathing exercises. researchers will compare dysphagia of two groups.

a growing body of literature indicates the existence of a highly stable, coordinative relation between respiration and oropharyngeal swallowing in healthy adults. the goal of this clinical trial is to explore the effect of active breathing exercises in stroke patients with respiratory rhythm disorder. patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. on this basis, the observation group will be given active breathing exercises. researchers will compare dysphagia of two groups.

Eligibility criteria:
inclusion criteria: * diagnosed with respiratory rhythm disorder * age ≥ 18 years; * meeting the diagnostic criteria of stroke; * any degree of dysphagia at admission; * steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment. * transferred out within three weeks of hospitalization in the neurology department. exclusion criteria: * complicated with other neurological diseases; * tracheostomy tube plugged; * unfeasible to the support of parenteral nutrition; * simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
va106483 and alpha blocker interaction study in elderly males

Conditions: Nocturia

Summary: the main purpose of this study is to investigate whether the hypotensive effects of an alpha-blocker are increased when va106483 is given at the same time.

va106483 is intended to be used as a treatment for patients suffering from nocturia (defined as waking to urinate at least once per night between periods of sleep). nocturia is a condition that often worsens as sufferers get older. this may be due to an over-active bladder muscle, the bladder being able to hold less urine at night-time or over production of urine in the bladder at night. some of the treatments available for nocturia have side-effects which make them unsuitable for elderly patients. these side-effects have not been seen in studies with va106483, which makes it potentially suitable for treating elderly patients. nocturia is commonly associated with benign prostatic hypertrophy (or bph, a non-cancerous enlargement of the prostate gland, which often results in problems passing water). of the patients who suffer from bph, an estimated 40-85% experience the symptoms of waking at night to pass water. treatments which are commonly prescribed for bph include alpha-blockers which work by improving urine flow by a muscle relaxant effect. alpha-blockers are known to cause hypotension (lowering of blood pressure which can cause dizziness in some patients) . since it is likely that subjects may be co-prescribed va106483 and alpha-blockers, the purpose of this study is to determine that giving va106483 does not increase the hypotensive effects of alpha-blockers

Eligibility criteria:
inclusion criteria: * male aged 65 years of age and above * no clinically important abnormal physical, laboratory or vital sign findings in the opinion of the investigator * provision of written informed consent to participate * no recent alpha-blocker therapy * not taking any concomitant medication known to be a cytochrome 3a4 inhibitor * not taking any prescribed or over the counter medications unless agreed with the investigator and sponsor * no evidence of serious pathology or disease including poorly controlled endocrine disorders; active liver or biliary disease or severe kidney problems; syndrome of inappropriate antidiuretic hormone secretion * no history of orthostatic hypotension or syncope. * no known hypersensitivity to the imp or alpha blocker, including severe lactose intolerance. * no history of drug or alcohol abuse * negative for hiv, hepatitis b or c

Keywords: nocturia hyptotension elderly males